Keywords: Tumors (Pre-Treatment), Diagnosis/Prediction, NODDI
Motivation: Isocitrate dehydrogenase (IDH) mutation status is crucial for diffuse glioma prognosis and treatment, yet non-invasive prediction methods remain underdeveloped.
Goal(s): To assess the diagnostic efficacy of APT and NODDI imaging, along with their combination, for predicting IDH mutation status in diffuse gliomas.
Approach: Fifty diffuse glioma patients (25 IDH wild-type and 25 IDH-mutant) were recruited. APT and NODDI parameters in tumor parenchyma were compared between groups, and logistic regression was used to combine optimal parameters to build a predictive model.
Results: The combined APT and ICVF approach achieved the highest diagnostic efficacy, with an AUC of 0.794.
Impact: The combined APT and NODDI imaging approach offers an accurate, non-invasive method for predicting IDH mutations in diffuse gliomas, improving diagnosis and enabling personalized treatment.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords